Clinical Trial Update: A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2b/3 clinical trial evaluating T3D-959 for mild-to-moderate Alzheimer's disease is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• T3D-959 (T3D-959)

Snippet

Sponsor: T3D Therapeutics, Inc. | Conditions: Alzheimer's Disease | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING